印度 Lupin 鲁宾
鲁宾有限公司是一家以创新为主导，在世界范围内为发达国家和发展中国家提供广泛的高品质，低价位的仿制及品牌制剂和原料药的跨国公司。
在鲁宾，我们努力通过在世界范围内为患者提供可负担、可获得的药品，为人们营造健康的生活。我们致力于发现、研发和使创新药物商业化来满足未能被满足的医疗需求。
当成为世界上最大的结核药生产商时，鲁宾首次得到了认可。多年来，公司已提升了价值链，不仅在中间体和原料药方面有所建树，也充分利用其优势在全球范围内建立起制剂业务，足迹遍布美国、印度、日本、澳大利亚、英国、德国、独联体等。

我们的优势：

完全综合性制药公司
??在仿制药、新化学实体、新型给药系统、新生物实体、研究等领域建立了强大的科研基地
??获得国际管理机构批准的世界级的GMP标准生产设施，包括美国，
??以坚实的科技和专业知识为依托，提高产品科技含量，生产出更具创新性的产品
??强有力的全球足迹：美国、印度、日本、澳大利亚、英国、德国、独联体等
??大型动态营销队伍和?强大的分销网络

Lupin是由拥有化学硕士学位的亿万富翁、董事长Desh Bandhu Gupta于1968年一手创办。根据其2011年度报告,Lupin在国内市场拥有大约4000名医疗销售代表。Gupta及其家族控制了该公司46.96%的股份。

 
Headquartered in Mumbai, India, Lupin Limited today is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world.

Dr. Desh Bandhu Gupta's vision and dream to fight life threatening infectious diseases and to manufacture drugs of the highest social priority led to the formation of Lupin in the year 1968. His Vision, his inimitable commitment and verve have steered Lupin to achieving the distinction of becoming one of the fastest growing Generic pharmaceutical companies globally.

Lupin first gained recognition when it became one of the world's largest manufacturers of Tuberculosis drugs. The Company today has significant market share in key markets in the Cardiovascular (prils and statins), Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAIDs therapy segments, not to mention global leadership positions in the Anti-TB and Cephalosporins segments. The Company's R&D endeavours have resulted in significant progress in its NCE program. The Company's foray into Advanced Drug Delivery Systems has resulted in the development of platform technologies that are being used to develop value-added generic pharmaceuticals. Lupin's world class manufacturing facilities, spread across India and Japan, have played a critical role in enabling the companies realize its global aspirations. Benchmarked to International standards, these facilities are approved by international regulatory agencies like US FDA, UK MHRA, Japan's MHLW, TGA Australia, WHO, and the MCC South Africa.

Our Drugs and products reach over 70 countries in the world. Today, Lupin has emerged as the 5th largest and the fastest growing Top 5 company in the U.S (by prescriptions), the only Asian company to achieve that distinction. The company is also the fastest growing, top 5 pharmaceutical players in India (ORG IMS) and the fastest growing top 10 Generic players in Japan and South Africa. (IMS), Today, Lupin also has the unique distinction of being the fastest growing top 10 Generics players in the two largest pharmaceutical markets of the world – The U.S (ranked 5th by prescriptions & growing at 52 %) and Japan (ranked 7th and growing at 23%). Lupin's Consolidated Revenues and Profit after Tax were Rs. 57,068 million and Rs. 8,626 million for FY 2010-11.

Going forward, our research backbone, best-in-class class manufacturing capabilities, marketing and servicing depth globally will stand us in good stead. The company will continue to focus on identifying and developing niche segments, a differentiated product portfolio in all its chosen markets backed up by strategic partnerships and in-licensing, and investment in new areas such as biosimilars - well on-course to becoming a global pharmaceutical powerhouse.